BLOG / 🇺🇸 United States / ma activity · · daily

US Merger & Acquisition SEC Filings — November 05, 2026

USA M&A & Takeover Activity

By Gunpowder Editorial ·

21 high priority 21 total filings analysed

Executive Summary

The US M&A landscape on November 5, 2026, is defined by a surge in deal completions and SPAC activity, with 21 filings spanning closed transactions, new business combinations, and strategic pivots.

Key themes include the completion of transformative mergers—Vivmark Residential (EQR/AVB) and Sunrise Realty Trust—and the closing of bolt-on acquisitions like Vistra's $5.5B Cogentrix purchase and Willdan's $285M Mantis deal, signaling robust strategic appetite. However, financial performance is mixed: IonQ delivered record revenue growth of 336% YoY but a massive adjusted EBITDA loss, while NCR Voyix lowered revenue guidance to the bottom of its range. SPAC activity remains vibrant with new deals (Armada/Brains at $750M pre-money) and IPO closings (BHAV II's $100M), but risks persist, including going-concern warnings for Patriot Glass and BHAV II, and Nasdaq listing deficiencies for Pantages. Insider and capital allocation signals are sparse, but the EQR/AVB merger's credit upgrade to 'A' and Sunrise's reduced incentive fees highlight efforts to optimize capital structures.

Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →

Filing types in this digest: 8-K

Tracking the trend? Catch up on the prior US Merger & Acquisition SEC Filings digest from November 04, 2026.

Investment Signals (12)

  • Vivmark Residential (EQR/AVB) (BULLISH)
    ▲

    Merger completed with S&P upgrade to 'A' from 'A-', Core FFO per share up 5.1% YoY, and renewal rate achieved at 5.3% in Q3 2026, indicating strong post-merger operating momentum

  • IonQ ↓ (BULLISH)
    ▲

    Revenue surged 336% YoY to $173.8M, sixth consecutive record quarter, FY2026 guidance raised to $505-515M (110% YoY growth), and backlog more than doubled to $1.2B, despite adjusted EBITDA loss

  • Vistra ↓ (BULLISH)
    ▲

    Completed $5.5B acquisition of Cogentrix, adding 5,500 MW of natural gas generation across PJM, ISO-NE, and ERCOT, expanding portfolio to ~50,000 MW and enhancing scale

  • Completed merger with Southern Realty Trust, creating pro forma book value of ~$285M and loan commitments of ~$604M, with reduced incentive fee (20% to 17.5%) and hurdle rate (8% to 7%), aligning management with shareholders

  • ▲

    Closed $285M cash acquisition of Mantis Innovation, expanding energy efficiency and building controls services into data centers and industrial sectors, with guidance update expected on Nov 5 earnings call

  • Definitive agreement to merge with Brains Bioceutical at $750M pre-money equity value, with 100% rollover and Nasdaq listing under 'BAPI', targeting Q2 2027 close

  • Closed $100M IPO with $100.5M in trust, targeting high-growth sectors like robotics, quantum computing, and advanced energy, providing a new vehicle for M&A

  • NCR Voyix ↓ (NEUTRAL)
    ▲

    Non-GAAP EPS improved to $0.32 from $0.30 YoY, and remaining contract value reached ~$440M, but revenue guidance lowered to bottom of range

  • Cash position of $234.7M funds operations into Q1 2029, and TX2100 received FDA Fast Track for HHT, with Phase 1a showing favorable safety

  • Narrowed net loss to $24.7M from $27.9M YoY, extended cash runway into Q2 2028, and key catalysts (VY7523 tau PET data in Q4 2026) pending

  • ▲

    Divested EveryLife for $5.5M, becoming pure fintech, but only 18% cash upfront and positive cash flow expected in 2027

  • iSpecimen ↓ (NEUTRAL)
    ▲

    Acquired AI products for $4.5M, entering AI-powered disease intelligence, but dilution and going-concern risks persist

Risk Flags (10)

  • NCR Voyix↓ [HIGH RISK]
    ▼

    Full-year 2026 revenue guidance lowered to bottom of $2,188-2,303M range, signaling weakening demand and potential further cuts

  • PSQ Holdings↓ [HIGH RISK]
    ▼

    Only $1.0M cash upfront from $5.5M sale, with $4.5M note dependent on buyer's financing; positive cash flow not expected until 2027

  • Transportation & Logistics Systems (Patriot Glass) [HIGH RISK]
    ▼

    Auditor issued going-concern warning with $645K accumulated deficit, $150K working capital deficit, and revenue down 14.7% YoY

  • Pantages Capital Acquisition [HIGH RISK]
    ▼

    Nasdaq listing deficiency for <400 holders, compliance deadline March 1, 2027, with delisting risk if not resolved

  • ▼

    Auditor going-concern doubt due to accumulated deficit of $105K and requirement to complete business combination by June 30, 2027 or liquidate

  • ▼

    12.9M shares redeemed (~$137M), leaving only $46M in trust, significantly reducing deal capacity and increasing risk of failure to find a target

  • iSpecimen↓ [HIGH RISK]
    ▼

    Going-concern uncertainty, potential Nasdaq listing non-compliance, and dilution from 2.9M shares issued at $0.86/share (implied)

  • Chairman Devin Nunes resigned, leaving board with only 3 independent directors and one vacancy, potential governance concerns

  • ▼

    Amendment allows listing on NYSE or Nasdaq, but no financial terms disclosed; deal still subject to approvals

  • Voyager Therapeutics↓ [MEDIUM RISK]
    ▼

    Collaboration revenue down 70% YoY to $4.0M, and cash declined 34% from year-end 2025, though runway extended

Opportunities (10)

  • IonQ↓ (OPPORTUNITY)
    ◆

    Record revenue growth and raised guidance, with $3.7B pro forma cash after $2B equity offering, positions it to accelerate quantum computing commercialization; watch for continued backlog conversion

  • Vistra↓ (OPPORTUNITY)
    ◆

    Cogentrix acquisition adds 5,500 MW of gas generation in key markets, enhancing portfolio and likely accretive to earnings; integration and synergy details may come on next earnings call

  • Sunrise Realty Trust↓ (OPPORTUNITY)
    ◆

    Merger creates larger commercial real estate lender with reduced fees, potentially improving earnings and valuation; integration costs may be near-term but synergies likely

  • $750M pre-money valuation for a cannabinoid API manufacturer with EU-GMP facility and pipeline; could attract biotech investors if clinical milestones achieved

  • Tectonic Therapeutic↓ (OPPORTUNITY)
    ◆

    Cash runway to Q1 2029 and FDA Fast Track for TX2100 in HHT; Phase 1b data and TX45 Phase 2 topline (Jan 2027) are near-term catalysts

  • Willdan Group↓ (OPPORTUNITY)
    ◆

    Mantis acquisition expands into data center energy efficiency, a high-growth area; guidance update on Nov 5 could provide accretion details

  • ◆

    New SPAC with $100M trust targeting advanced technologies; potential to merge with a high-growth private company in robotics or quantum

  • Voyager Therapeutics↓ (OPPORTUNITY)
    ◆

    Cash runway into Q2 2028 and multiple catalysts (VY7523 tau PET data Q4 2026, VY1706 dosing) could drive value if data positive

  • iSpecimen↓ (OPPORTUNITY)
    ◆

    AI acquisition for $4.5M could enhance offerings in disease intelligence; if going-concern resolved, potential turnaround

  • B. Riley Financial↓ (OPPORTUNITY)
    ◆

    Debt-for-equity swap reduces debt by $62M and simplifies balance sheet; Oaktree involvement may signal confidence

Sector Themes (6)

  • M&A Acceleration in Energy and Real Estate
    ◆

    Vistra's $5.5B Cogentrix deal and EQR/AVB merger completion highlight strategic consolidation in energy and residential REITs, driven by scale and credit upgrades (S&P raised EQR/AVB to 'A').

  • SPAC Resurgence with Mixed Outcomes
    ◆

    New SPAC IPOs (BHAV II $100M) and deals (Armada/Brains $750M) contrast with redemptions (Copley lost 74% of trust) and going-concern warnings (BHAV II), indicating investor selectivity.

  • Healthcare and Biotech M&A Activity
    ◆

    Armada/Brains ($750M), Tectonic's clinical progress, and Voyager's collaborations show continued interest in biotech, though revenue volatility (Voyager -70% YoY) remains a risk.

  • Divestitures and Strategic Pivots
    ◆

    PSQ Holdings sold EveryLife to focus on fintech, Inogen divested Rotech and changed CEO, and B. Riley swapped debt for equity, reflecting portfolio rationalization.

  • AI and Technology Acquisitions
    ◆

    iSpecimen acquired AI products for $4.5M, IonQ acquired SkyWater and Elisity, and BHAV II targets AI/robotics, underscoring AI's role in M&A.

  • Going-Concern and Listing Risks
    ◆

    Multiple companies (Patriot Glass, BHAV II, iSpecimen, Pantages) face going-concern or listing deficiencies, highlighting challenges for small-cap and SPAC entities.

Watch List (8)

  • Q3 earnings call on Nov 5, 2026, will provide updated guidance and Mantis acquisition details; watch for accretion and synergy targets.

  • 👁

    Post-earnings momentum; watch for integration of SkyWater and Elisity, and progress on $1.2B backlog; next earnings call in Q1 2027.

  • TX45 APEX Phase 2 topline data expected by end of January 2027; positive results could drive significant upside.

  • VY7523 tau PET data in Q4 2026 and VY1706 dosing in coming months; initial safety data Q1 2027.

  • Deal with Brains Bioceutical expected to close Q2 2027; watch for SEC S-4 filing and shareholder vote.

  • Pantages Capital Acquisition
    👁

    Must regain Nasdaq compliance by March 1, 2027; monitor for transfer agent documentation and potential delisting.

  • After massive redemptions, trust is only $46M; watch for new deal announcement or potential liquidation.

  • Must complete business combination by June 30, 2027; monitor for target announcement and SEC filings.

Filing Analyses (21)
EQUITY RESIDENTIAL 8-K mixed materiality 9/10

05-11-2026

Vivmark Residential (NYSE: VMRK), formed by the August 17, 2026 merger of equals between Equity Residential (EQR) and AvalonBay Communities (AVB), reported Q3 2026 results showing a sharp GAAP swing (EPS of $(1.27) vs. $0.96 in Q3 2025, driven by $0.92 per share of Merger-related costs) alongside Core FFO per share up 5.1% to $1.03. Operating performance was mixed: Merged Same Store revenue rose 2.4% and NOI rose 1.7% in Q3, but physical occupancy slipped to 95.8% from 95.9% a year earlier, and FFO per share fell 92.6% to $0.08 and nine-month FFO per share fell 42.5% to $1.77.

  • · Merger accounted for as a reverse acquisition: AVB is the accounting acquirer, so historical financials are AVB's alone, while EQR's assets and liabilities were recorded at fair value as of August 17, 2026.
  • · Merged Same Store renewal rate achieved stood at 5.3% in Q3 2026, with new lease change improving from (3.4%) in Q1 2026 to 0.4% in Q3 2026 and blended rate rising to 3.1%.
  • · S&P Global Ratings raised the long-term issuer credit rating to 'A' (stable outlook) from 'A-' for both AVB and EQR on August 18, 2026.
  • · EQR communities are excluded from the Same Store Portfolio until January 1, 2028, so reported same-store growth reflects the stabilized merged basis rather than the formal Same Store Portfolio.
  • · Full Year 2026 Merged Same Store expense guidance includes approximately $16M of California property tax reassessment costs, with an estimated $50M annual impact beginning in 2027.
  • · Q4 2026 projected EPS guidance is negative at $(0.95) to $(0.91), while projected Core FFO per share is $1.01 to $1.05.
  • · Full run-rate synergies expected by March 2028, 18 months after the Merger Date.
  • · Q3 2026 Merged Same Store turnover improved to 12.7% from 13.2%, and year-to-date turnover improved to 31.8% from 32.8%.
Vistra Corp. 8-K positive materiality 7/10

05-11-2026

Vistra Corp. (NYSE: VST) announced on October 30, 2026 that it completed its acquisition of Cogentrix Energy from funds managed by Quantum Capital Group, adding 10 natural gas generation facilities totaling approximately 5,500 MW across PJM, ISO New England, and ERCOT. The closing followed receipt of all required regulatory approvals and brings Vistra's generation portfolio to nearly 50,000 MW. The filing contains no quantitative financial metrics such as purchase price, revenue, or earnings impact, so the financial effect of the deal cannot be assessed from this document.

  • · Acquired assets include Patriot and Hamilton-Liberty (PJM, 881 MW each), Newington (ISO-NE, 624 MW), Bridgeport (ISO-NE, 558 MW), and Altura Cogeneration (ERCOT, 583 MW), the largest single facilities in the portfolio
  • · Vistra acquired 100% ownership, including the 25% interest in Patriot and Hamilton-Liberty not previously owned by Cogentrix
  • · Portfolio breakdown: PJM 2,302 MW across 5 plants, ISO-NE 1,750 MW across 4 plants, ERCOT 583 MW across 1 cogeneration plant
  • · Filing includes Items 2.01, 2.03, 3.02, and 7.01, indicating completion of acquisition, creation of a direct financial obligation, unregistered equity sales, and Regulation FD disclosure
NCR Voyix Corp 8-K mixed materiality 7/10

05-11-2026

NCR Voyix reported Q3 2026 results with revenue of $539 million, down from $677 million a year earlier, reflecting the completed Hardware Business Transition. Software and services revenue was flat at $500 million, recurring revenue rose to $428 million from $422 million, and Adjusted EBITDA slipped to $120 million from $123 million, while Non-GAAP diluted EPS improved to $0.32 from $0.30. Management lowered its full-year 2026 revenue expectation to the bottom of its $2,188 million to $2,303 million range, even as Remaining Contract Value reached approximately $440 million.

  • · Full-year 2026 revenue is now expected at the lower end of the $2,188M to $2,303M range, a negative revision in tone versus maintaining the full range
  • · Full-year 2026 outlook for Adjusted EBITDA ($432M to $447M), Non-GAAP diluted EPS ($0.89 to $0.92), and Adjusted Free Cash Flow ($190M to $220M) was maintained
  • · Aloha Next achieved its first live deployment at the Bruster's Bridgewater location
  • · Remaining Contract Value grew 151% year over year and 54% sequentially to approximately $440M
  • · Pro forma full-year 2026 revenue outlook is (2%) to 3% versus pro forma 2025
Black Spade Acquisition III Co 8-K neutral materiality 4/10

05-11-2026

Black Spade Acquisition III Co (BIII-UN) and its counterparties Astrum Space Inc and Astrum Networks Pte. Ltd. executed a First Amendment, dated November 5, 2026, to their Business Combination Agreement of August 27, 2026. The amendment allows the post-merger Listco Shares and BIII Warrants to be listed on either the NYSE or Nasdaq (via a new 'Qualified Stock Exchange' definition), replacing most prior NYSE-specific references, and updates the listing-application covenant in Section 7.03(b). The filing contains no dollar amounts, percentages, or period-over-period financial results.

  • · The 'Qualified Stock Exchange' is defined as NYSE (including NYSE American) or Nasdaq, as mutually agreed in writing (including by email) by the Company and BIII.
  • · Section 7.03(b) now requires BIII to use reasonable best efforts to obtain approval of the Listco Shares for listing on a Qualified Stock Exchange, with the listing application filed promptly and in any event before the Merger Effective Time.
  • · Several NYSE references (Sections 1.01, 5.08(c), 5.09, 7.03(a), 8.04(a) and the first sentence of 8.05(a)) are expressly left unchanged.
  • · Section 11.06 expense reference changes from 'New York Stock Exchange' to 'NYSE or Nasdaq'.
  • · The amendment takes effect on signing and is governed by the terms of the underlying Business Combination Agreement; it is a deal-structuring change rather than a final closing, with no completed transaction disclosed.
Armada Acquisition Corp. III 8-K positive materiality 8/10

05-11-2026

Armada Acquisition Corp. III (Nasdaq:AACI) and Brains Bioceutical Corp. announced a definitive business combination agreement valuing Brains at an implied pre-money equity value of approximately $750.0 million, with existing Brains shareholders expected to roll 100% of their equity into the combined company. The combined entity is expected to operate as Brains Therapeutics Corp. and trade on Nasdaq under ticker 'BAPI', with closing anticipated in Q2 2027 subject to shareholder and regulatory approvals. Brains brings EU-GMP cannabinoid API manufacturing in Kent, England and a pipeline spanning glaucoma, epilepsy, opioid use disorder and sleep disorders, though the transaction remains subject to conditions and no revenue or financial performance metrics were disclosed in the filing.

  • · Brains' API manufacturing facility in Kent, England is MHRA-inspected and registered and operated through wholly owned subsidiary BSPG Laboratories Limited
  • · Brains' APIs have been utilized in multiple third-party clinical studies supported by DMFs/ASMFs across the US, UK/EU, UAE, Japan, Australia and Brazil
  • · A pivotal bioequivalence study under an FDA Special Protocol Assessment showed once-daily extended-release methazolamide was bioequivalent to twice-daily immediate-release methazolamide
  • · The opioid use disorder program is in Phase 3 with approximately 450 subjects across seven sites
  • · Brains holds an exclusive option to negotiate a license to the opioid use disorder program
  • · The business combination is expected to close in Q2 2027, subject to Armada III and Brains shareholder approval, Form F-4 registration statement effectiveness, Nasdaq listing approval and other regulatory approvals
  • · Armada III's IPO prospectus was dated February 17, 2026 and filed February 18, 2026; its Form 10-K was filed March 20, 2026
  • · No revenue, earnings or other financial performance metrics for Brains were disclosed in the filing
PSQ Holdings, Inc. 8-K mixed materiality 6/10

05-11-2026

PSQ Holdings completed the sale of its EveryLife direct-to-consumer baby products business to FreeHold Brands for total consideration of $5.5 million, consisting of $1.0 million cash at closing and a $4.5 million asset-secured promissory note. The deal finalizes the company's 12-month transition to a pure fintech business focused on payments and consumer financing, with proceeds earmarked to strengthen the balance sheet and fund growth. However, only 18% of consideration is cash upfront, leaving $4.5 million dependent on FreeHold's financing and repayment, and management's expectation of positive monthly operating cash flow is not until 2027.

  • · Company now operates exclusively in payments and consumer financing following the divestiture
  • · Management expects to achieve positive monthly operating cash flow in 2027
  • · Risk disclosed that FreeHold Brands may not obtain financing or repay the note, in which case recovery depends on enforcing the security interest and collateral value
  • · Forward-looking statements reference the fiscal year ended December 31, 2025 Form 10-K for risk factors
  • · Investor contact: [email protected]; media contact: [email protected]
Inogen Inc 8-K mixed materiality 6/10

05-11-2026

Inogen, Inc. (Nasdaq: INGN) announced the appointment of COO Andy Reding as President and CEO and a member of the Board, succeeding Kevin Smith, effective November 5, 2026. The Board framed the transition around the need to improve performance, citing Reding's central role in the previously announced Rotech divestiture (September 2026) that is expected to shift Inogen toward a more streamlined commercial model. The filing contains no financial figures for the quarter; Q3 2026 results were to be announced separately the same day.

  • · Andy Reding joined Inogen as COO in July 2026, only months before being elevated to CEO
  • · Reding served as VP and General Manager of Hillrom Respiratory Health from 2015 to 2020
  • · Reding holds an MBA from the University of South Carolina and a bachelor's degree from Marquette University
  • · Board Chairperson Elizabeth Mora stated the company 'must do more to improve performance,' signaling current underperformance
  • · Q3 2026 financial results (quarter ended September 30, 2026) were to be announced separately with an investor call at 5:00 p.m. ET
  • · Forward-looking statements reference expected classification of the Rental Business as discontinued operations, anticipated net proceeds, and use of transaction proceeds from the Rotech divestiture
Willdan Group, Inc. 8-K neutral materiality 8/10

05-11-2026

Willdan Group completed its previously announced acquisition of Mantis Intermediate Holdings, LLC (dba Mantis Innovation) for $285 million in cash, subject to customary holdbacks and adjustments, after HSR waiting period expiration and satisfaction of closing conditions. Mantis, headquartered in Houston, provides building controls, energy efficiency, energy advisory, and facility management to commercial and industrial customers across manufacturing, food and beverage, healthcare, and data centers. Willdan said it will provide additional transaction details and updated financial guidance on its Q3 earnings call scheduled for November 5, 2026; no revenue, margin, or accretion figures were disclosed in this release.

  • · Transaction closed following expiration of the applicable Hart-Scott-Rodino waiting period and satisfaction of customary closing conditions
  • · Mantis is headquartered in Houston, Texas
  • · Mantis serves manufacturing, food and beverage, healthcare, data centers, and other energy-intensive industries
  • · Jefferies LLC served as exclusive financial advisor to Mantis
  • · Willdan will provide additional transaction details and updated financial guidance during its Q3 earnings conference call on November 5, 2026
  • · No revenue, EBITDA, purchase multiple, or accretion/dilution figures were disclosed in the release
IonQ, Inc. 8-K mixed materiality 9/10

05-11-2026

IonQ reported record 3Q26 GAAP revenue of $173.8 million, up 336% year-over-year, its sixth consecutive record quarter, and raised FY2026 revenue guidance to $505-$515 million (expecting 110% YoY quantum computing growth). However, the quarter showed a sharp split: GAAP net income of $564.0 million and GAAP EPS of $1.42 were driven by non-cash warrant mark-to-market gains, while Adjusted EBITDA was a loss of ($133.6) million and Adjusted EPS was ($0.29). The company also closed its SkyWater acquisition (contributing $83.5 million in foundry revenue) and acquired Elisity for quantum security, ending with $1.7 billion in cash and investments ($3.7 billion pro-forma for a $2.0 billion October equity offering).

  • · Adjusted EPS of ($0.29) and Adjusted EBITDA loss of ($133.6) million contrast with GAAP EPS of $1.42, which was inflated by non-cash warrant mark-to-market gains
  • · Cash was $1.7 billion at Sept 30, 2026, rising to $3.7 billion pro-forma for the $2.0 billion equity offering closed October 16, 2026
  • · Remaining performance obligations (backlog) more than doubled to $1.2 billion
  • · Quantum computing represented approximately two-thirds of new contract dollars signed by the IonQ Platform segment
  • · SkyWater Foundry Services contributed $83.5 million in revenue; non-IonQ quantum customer revenue grew more than 30% YoY
  • · DARPA Stage C participation carries a potential program value of up to $300 million
  • · NVIDIA will deploy a Superion 256 system as the first on-premise quantum computer at its Accelerated Quantum Research Center
  • · Conference call scheduled November 5, 2026 at 4:30 PM Eastern; replay available until November 19, 2026
Voyager Therapeutics, Inc. 8-K mixed materiality 6/10

05-11-2026

Voyager Therapeutics reported Q3 2026 collaboration revenue of $4.0M, down 70% YoY from $13.4M, as Neurocrine collaboration activities transitioned beyond the research phase. The company narrowed its net loss to $24.7M from $27.9M YoY, driven by lower R&D ($24.4M, -32% YoY) and G&A ($6.1M, -25% YoY) expenses, extending cash runway into Q2 2028 with $132.1M in cash and securities. However, the cash balance declined 34% from $201.7M at year-end 2025, and key clinical catalysts (VY7523 tau PET data in Q4 2026, VY1706 first dosing) remain pending enrollment.

  • · VY7523 tau PET imaging efficacy data expected in Q4 2026; last patient visit complete
  • · VY1706 patient screening ongoing in US; dosing expected in next few months, initial acute safety data in Q1 2027
  • · Neurocrine's NBIB-'223 FA program expected to enter Phase 1 in coming months with initial patient-level data in 2027
  • · Total operating expenses fell to $30.4M in Q3 2026 from $44.0M in Q3 2025
  • · Operating loss narrowed to $26.4M from $30.6M YoY
  • · Total assets declined to $177.1M from $252.3M at year-end 2025
  • · Total stockholders' equity fell to $135.1M from $196.1M
  • · Upcoming presentations: Guggenheim Healthcare Innovation (Nov 9), Stifel Healthcare (Nov 10), CTAD (Nov 16-19), Antibody Engineering & Therapeutics (Dec 13-16), all 2026
  • · Robin Swartz appointed President in October 2026 as part of planned CEO succession
B. Riley Financial, Inc. 8-K neutral materiality 7/10

05-11-2026

B. Riley Financial's subsidiary BRF Finance Co., LLC agreed on November 3, 2026 to sell its entire stake in Great American Holdings, LLC — 170,524 Class B Preferred Units and 397,593 Class A Common Units — to Oaktree-affiliated purchasers (SSF III, Opps XII, VOF) for an aggregate purchase price of $62,250,000.00. Immediately after closing, BR Holdings will use the proceeds to repay and cancel the same $62,250,000 principal amount of debt owed to Oaktree-affiliated lenders under the February 2025 Credit Agreement, with all remaining indebtedness and liens staying in force. As part of the deal, Bryant Riley will resign from the Company's board effective at closing, and the transaction is structured as a debt-for-equity swap rather than a Fundamental Change under the Company LLC Agreement.

  • · Seller is BRF Finance Co., LLC, with BR Financial Holdings, LLC as affiliate co-party; Purchasers are Oaktree-affiliated entities (SSF III, Opps XII, VOF)
  • · Lenders under the Credit Agreement are also Oaktree affiliates, making this a related-party debt-for-equity transaction
  • · Closing scheduled for 10:00 a.m. Eastern Time on the date of the agreement (November 3, 2026), subject to conditions
  • · All liens/pledges on the Acquired Units under the Credit Agreement and Guarantee and Collateral Agreement will be released on the Closing Date
  • · Except for the Repaid Loan Amount, all other indebtedness, obligations, liabilities and Encumbrances under the Credit Agreement remain in full force and effect
  • · Transaction is expressly stated not to constitute a Fundamental Change under the Company LLC Agreement
  • · Seller delivers IRS Form W-9 and an assignment of membership interests; parties exchange a cross receipt and direction letter
  • · No brokerage or finders' fees incurred by either Seller Parties or Purchaser Parties
Renatus Tactical Acquisition Corp I 8-K neutral materiality 3/10

05-11-2026

Renatus Tactical Acquisition Corp I (RTACU), a Cayman Islands blank-check company listed on Nasdaq, disclosed that Chairman and director Devin G. Nunes resigned effective October 31, 2026, and the company stated the resignation was not due to any dispute or disagreement over operations, policies or practices. The board now comprises three independent directors and one non-independent director, leaving one vacant seat, and the company is actively searching for a new independent director. The filing is a governance update with no financial figures or merger terms disclosed, despite the preliminary Merger/Acquisition tag.

  • · Resignation effective October 31, 2026; 8-K filed November 5, 2026
  • · Company is a blank-check (SIC 6770) emerging growth company incorporated in the Cayman Islands
  • · Securities trade on Nasdaq under RTACU, RTAC and RTACW
  • · Company previously changed names multiple times, including Renatus Yorkville Tactical Acquisition Corp I (name change dated January 21, 2025)
  • · Principal executive offices listed at 1825 Ponce de Leon Blvd, Suite 260, Coral Gables, FL 33134
  • · SEC file number 001-42650; CIK 0002035173
iSpecimen Inc. 8-K mixed materiality 7/10

05-11-2026

iSpecimen Inc. (Nasdaq: ISPC) completed the acquisition of two AI products from Foldlab AI Ltd. on November 2, 2026 — an AI agent for identifying disease-associated proteins and an AI model for predicting and monitoring disease trends — marking its entry into AI-powered disease intelligence. The aggregate purchase price is $4.5 million, comprising $750,000 cash at closing, up to $1.25 million in two $625,000 milestone payments, and $2.5 million in 2,907,977 common shares issued November 5, 2026 under Regulation S/Section 4(a)(2) with a five-year lock-up. However, the filing carries notable risk disclosures including potential dilution from the stock consideration, possible failure to maintain Nasdaq listing compliance, a potential reverse stock split, and going-concern uncertainty requiring additional financing.

  • · Asset Purchase Agreement dated September 4, 2026; acquisition approved by stockholders on October 9, 2026
  • · Acquired full technology stack including source code, model weights, data rights, repositories, credentials and IP
  • · Shares issued in private placement under Regulation S and Section 4(a)(2); not registered under the Securities Act
  • · Shares subject to voting rights agreement with the Company
  • · Forward-looking risks cited: potential substantial dilution, Nasdaq continued listing compliance, possible reverse stock split, and going-concern/need for additional financing
  • · Company's 10-K for year ended December 31, 2025 was filed April 1, 2026
Transportation & Logistics Systems, Inc. 8-K mixed materiality 7/10

05-11-2026

Transportation & Logistics Systems (TLSS) filed an 8-K disclosing audited financials of Patriot Glass Solutions, LLC (dba A1 Glass Coating), the window-tint business it is acquiring/merging with. Patriot Glass revenue fell 14.7% YoY to $2,607,600 in FY2025 from $3,056,670 in FY2024, but the company swung to net income of $422,044 from a net loss of $(940,041), aided by sharply lower operating expenses and a $72,355 debt-extinguishment gain. However, the auditor issued a going-concern warning citing a $645,380 accumulated deficit, $26,152 members' deficit and $150,574 working capital deficit as of December 31, 2025.

  • · Auditor Salberg & Company, P.A. (PCAOB ID No. 106) issued a going-concern qualification on Patriot Glass's financial statements.
  • · Patriot Glass was formerly named Mobile Tint LLC; renamed November 29, 2023.
  • · On January 30, 2025, former 80% parent C-Bond Systems transferred its membership interest to Badcer Ops, Inc. via strict foreclosure under UCC Section 9-620, settling outstanding debt.
  • · No push-down accounting was applied for the change of control; acquisition adjustments reflected at parent level.
  • · FY2024 results included $529,402 in goodwill/intangible impairment charges and a $316,572 related-party management fee, both absent in FY2025.
  • · Accounts receivable rose to $303,858 from $191,653 while inventory fell to $26,438 from $45,532.
  • · Notes payable current portion dropped to $20,248 from $287,468, offset by new $291,000 related-party notes payable.
  • · FY2025 capital expenditures were $49,552 vs $42,157 in FY2024.
  • · Cash paid for interest was $59,002 in FY2025 vs $68,958 in FY2024; no income taxes paid in either year.
  • · Distribution to parent of $80,870 in FY2025 and $136,707 to former parent in FY2024.
Tectonic Therapeutic, Inc. 8-K mixed materiality 6/10

05-11-2026

Tectonic Therapeutic reported Q3 2026 financial results with cash and cash equivalents of $234.7 million as of September 30, 2026 (up from $227.1 million at June 30, 2026, aided by ~$22.3 million in net ATM proceeds), expected to fund operations into Q1 2029. However, net loss widened to $21.3 million from $19.0 million a year earlier, as R&D rose to $17.4 million from $16.9 million and G&A increased to $6.0 million from $5.0 million. Clinically, TX2100 showed favorable Phase 1a safety/PK results and received FDA Fast Track designation for HHT, while TX45's APEX Phase 2 topline results in PH-HFpEF are expected by end of January 2027.

  • · TX2100 Phase 1a Part A showed no serious adverse events, no severe treatment-emergent adverse events, no clinically significant vital sign changes, and no anti-drug antibodies detected across all six single-dose cohorts
  • · FDA granted TX2100 Fast Track designation for HHT in September 2026 and cleared the IND for the Phase 1b trial in August 2026
  • · TX45 ALPINE Phase 2a trial: open-label, multinational, 16-week, up to 25 PH-ILD patients, dosing at 300 mg SC once monthly, primary endpoint change in PVR at Week 16
  • · TX45 APEX Phase 2 trial enrollment completed June 2026; IDMC recommended in July 2026 that the trial continue without modification
  • · TX2100 TERRA Phase 1b: ~20 HHT patients, once-weekly SC dosing for 24 weeks, interim topline expected by year-end 2027
  • · TIDAL Phase 2 trial in moderate-to-severe HHT expected to initiate in early 2027
  • · R&D increase attributed to higher employee-related and stock-based compensation expenses and headcount, partially offset by lower CDMO costs for TX2100 and lower clinical supply costs for TX45
  • · HHT affects an estimated 75,000 people in the U.S. and has no approved therapies; PH-HFpEF affects ~1.4 million patients in the U.S., with CpcPH accounting for about one third to one half
Sunrise Realty Trust, Inc. 8-K positive materiality 9/10

05-11-2026

Sunrise Realty Trust (SUNS) completed its merger with Southern Realty Trust (SRT), issuing 8,464,975 shares to SRT holders who now own approximately 38.5% of the combined company, while pre-merger SUNS stockholders retain approximately 61.5%. The combined company has pro forma book value of approximately $285 million, total assets of approximately $534 million, and total loan commitments of approximately $604 million across 14 loans. The amended management agreement reduces the incentive fee from 20% to 17.5% and the hurdle rate from 8.0% to 7.0%, and cuts the base management fee by $250,000 per quarter for four quarters ($1.0 million aggregate), though the transaction also involves integration costs and risks.

  • · Each outstanding SRT share was converted into 1.45 shares of SUNS common stock plus $0.05 cash per share from SUNS Manager.
  • · The Stub Period Dividend of $0.09 per share is payable November 5, 2026, to stockholders of record on November 2, 2026.
  • · Certain former SRT stockholders holding approximately 32% of SRT stock agreed to a 120-day lock-up on SUNS shares received.
  • · The SUNS Board was expanded by one seat with the appointment of Howard Sudnow as an independent director designated by SRT.
  • · The merger consideration shares were not registered under federal securities laws and may be resold only under an effective registration statement or exemption.
PANTAGES CAPITAL ACQUSITION Corp 8-K negative materiality 6/10

05-11-2026

Pantages Capital Acquisition Corporation disclosed that Nasdaq granted it an extension to regain compliance with Listing Rule 5450(a)(2), which requires at least 400 Total Holders for continued listing on the Nasdaq Global Market. The company must file transfer-agent or independent documentation showing a minimum of 400 Total Holders on or before March 1, 2027; failure would trigger written notice of delisting, subject to appeal to a Listing Qualifications Panel. The notice follows a September 2, 2026 deficiency letter and the company's October 16, 2026 compliance plan, and no financial or operating metrics were reported.

  • · Nasdaq deficiency notice received September 2, 2026 under Listing Rule 5450(a)(2)
  • · Compliance plan submitted to Nasdaq on October 16, 2026, ahead of the October 19, 2026 deadline
  • · Extension notice received October 27, 2026; 8-K filed November 5, 2026
  • · Company is a Cayman Islands-incorporated blank check company (SIC 6770) listed on Nasdaq under file number 001-42425
  • · Class A ordinary shares have $0.0001 par value; each whole right entitles holder to one-fifth of one Class A ordinary share
  • · Company qualifies as an emerging growth company
BHAV Acquisition Corp II 8-K mixed materiality 6/10

05-11-2026

BHAV Acquisition Corp II, a Cayman Islands blank-check company, closed its $100,000,000 IPO of 10,000,000 units at $10.00 per unit on October 30, 2026, alongside a $2,250,000 private placement of 225,000 units to sponsor BHAV Partners II LLC, for total offering proceeds of $102,250,000. Of this, $100,500,000 ($10.05 per unit) was placed in a trust account with Continental Stock Transfer & Trust Company. However, the auditor flagged substantial doubt about the company's ability to continue as a going concern, as it must complete a business combination by June 30, 2027 or liquidate, and it reported an accumulated deficit of $105,794 with no operating revenue.

  • · Company must complete a business combination by June 30, 2027 or cease operations and liquidate, raising substantial doubt about going concern per auditor WithumSmith+Brown
  • · Company incorporated as a Cayman Islands exempted company on May 25, 2026
  • · Target sectors include advanced/industrial robotics, EVs, drones/UAS, fintech, quantum computing, advanced computing infrastructure, and advanced energy technologies (geothermal, small modular nuclear reactors, energy storage, grid infrastructure)
  • · 350,000 Class A ordinary shares issued to Maxim Group designee as underwriting compensation
  • · 500,000 Class B ordinary shares subject to forfeiture if over-allotment option is not exercised in full or in part
  • · 10,000,000 Class A shares subject to possible redemption at $10.05 per share
  • · Registration statement declared effective October 28, 2026; sponsor private placement agreement dated October 28, 2026
  • · Audited balance sheet as of October 30, 2026 included as Exhibit 99.1
Copley Acquisition Corp 8-K mixed materiality 7/10

05-11-2026

Copley Acquisition Corp shareholders approved an amendment extending its business combination deadline up to 12 monthly extensions from November 2, 2026 to November 2, 2027, with each extension requiring a $200,000 trust deposit; the sponsor issued a $2,400,000 promissory note to fund these deposits. However, holders of 12,889,720 Class A shares redeemed at approximately $10.63 per share for an aggregate of approximately $137,119,390.16, leaving only approximately $46,241,913.77 in the Trust Account and 4,550,280 Class A shares outstanding — a substantial reduction in trust capital that materially shrinks the deal capacity for any initial business combination.

  • · Extraordinary General Meeting convened October 29, 2026 and adjourned to November 2, 2026
  • · Extension Amendment became effective November 2, 2026
  • · Promissory note matures upon the earlier of closing of the initial business combination and the Company's liquidation
  • · First $200,000 drawdown extends the deadline from November 2, 2026 to December 2, 2026
  • · Trust Account liquidation date extended from November 2, 2026 to November 2, 2027
  • · Extension permits up to 30 months after the consummation of the IPO
  • · Company is a Cayman Islands blank check company
Leader's Advantage Acquisition Corp. 8-K neutral materiality 3/10

05-11-2026

Leader's Advantage Acquisition Corp., a Cayman Islands blank-check SPAC focused on healthcare, filed an 8-K announcing that commencing November 6, 2026, holders of its IPO units (LEDRU) may elect to separately trade the underlying Class A ordinary shares (LEDR) and redeemable warrants (LEDRW) on Nasdaq. Each whole warrant is exercisable for one Class A share at $11.50. The filing contains no financial results, deal terms, or business combination announcement — it is a routine structural/administrative update, so no period-over-period financial comparison applies.

  • · Separate trading of shares and warrants commences November 6, 2026; unseparated Units continue trading as LEDRU
  • · No fractional warrants will be issued upon separation — only whole warrants will trade
  • · Holders must have their brokers contact transfer agent Odyssey Transfer & Trust Company to separate Units
  • · Company is a blank-check company incorporated October 29, 2025, in the Cayman Islands; intends to focus on a healthcare business combination with an established business of scale plus first-in-class drug candidates
  • · Company is an emerging growth company; SEC file number 001-43442; EIN 98-1898982; SIC code 6770 (Blank Checks)
  • · Filing signed by Dr. Paritosh Chakrabarti as Chairman and CEO; press release attached as Exhibit 99.1
BHAV Acquisition Corp 8-K neutral materiality 6/10

05-11-2026

BHAV Acquisition Corp, a Cayman Islands SPAC, and Nemi Corp., a physical AI and manufacturing company, announced a definitive business combination agreement under which BHAV and Nemi are expected to combine and Nemi will become a public company, with BNC Motors PV. Ltd, an Indian private limited company, also party to the agreement. The filing contains no quantitative financial results, valuation, or deal consideration figures, and the transaction remains subject to shareholder approval, an SEC Form S-4 registration, and other closing conditions.

  • · Filing lists BHAV's Nasdaq tickers as BHAVU (units), BHAV (Class A ordinary shares), and BHAVR (rights)
  • · BHAV's initial public offering prospectus is dated March 18, 2026
  • · Filing is made under Rule 425, indicating communications related to a registered business combination
  • · Nemi is described as a physical AI and manufacturing company; forward-looking statements reference quantum security and infrastructure
  • · Risk factors cite political or economic instability in emerging markets including the Middle East and possible Cayman Islands governance risks

Get daily alerts with 12 investment signals, 10 risk alerts, 10 opportunities and full AI analysis of all 21 filings

$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.

More from: US Merger & Acquisition SEC Filings

🇺🇸 More from United States

View all →